Following U.S. Stocks are trending during the Recent trade: Gray Television, Inc (NYSE:GTN), Allied Nevada Gold Corp (NYSEMKT:ANV), Second Sight Medical Products Inc (NASDAQ:EYES), Arena Pharmaceuticals, Inc (NASDAQ:ARNA)
Their insights are depicted underneath:
Gray Television, Inc (NYSE:GTN)’s shares picked up 2.70%, and is now trading at $12.94.
Gray Television Inc. (GTN), declared that it released its earnings results for the quarter ending December 31, 2014 on Thursday, March 5, 2015.
Gray Television Inc. (GTN), operates as a television broadcast corporation in the United States. As of February 1, 2015, the corporation owned and operated television stations in 44 television markets broadcasting a total of 140 programming streams, counting 26 associates of the CBS Network, 24 associates of the NBC Network, 16 associates of the ABC Network, and 10 associates of the FOX Network.
Allied Nevada Gold Corp (NYSEMKT:ANV), declined -5.68%, and is now trading at $0.839. The stock has the beta value of 0.08, and its volatility for the week is 7.47%, while for the month it is 7.75%. The company has the market capitalization of $112.30M. The mean recommendation of analysts for this stock is 3.60.(where 1=Buy, 5=Sale).
Allied Nevada Gold Corp., a gold producer, is engaged in the mining, development, and exploration of properties in Nevada. The corporation’s principal products comprise unrefined gold and silver bars.
Second Sight Medical Products Inc (NASDAQ:EYES), dwindled -2.98%, and is now trading at $16.90.
According to BUSINESS WIRE, Second Sight Medical Products, Inc. (EYES), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, declared that two newly approved centers, located in Camposampiero and Florence, have successfully accomplished their first commercial implants of the Argus II Retinal Prosthesis System (“Argus II”) in patients with outer retinal degeneration.
“We are thrilled to see the expanded availability of Argus II in Italy,” stated Dr. Robert Greenberg, Chief Executive Officer of Second Sight. “By offering Argus II in Italy, we are able to provide patients with outer retinal degeneration the chance to lead more independent lives, which can be life changing for these patients.”
Second Sight Medical Products, Inc. was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as RP. Second Sight’s mission is to develop, manufacture, and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence.
Arena Pharmaceuticals, Inc (NASDAQ:ARNA), dipped -1.16%, and is now trading at $4.27.
According to PRNewswire, Arena Pharmaceuticals, Inc. (ARNA), offered a corporate update and stated financial results for the fourth quarter and full year ended December 31, 2014.
Fourth Quarter 2014 Financial Results:
- Proceeds totaled $9.2 million, counting $3.8 million in net product sales of BELVIQ, of which $3.2 million represented 31.5% of Eisai’s net product sales and $0.6 million related to redemptions of the 15-day free voucher and product samples.
- Research and development expenses totaled $27.8 million.
- General and administrative expenses totaled $8.9 million.
- Net loss was $32.1 million, or $0.15 per share.
- At December 31, 2014, cash and cash equivalents totaled $163.2 million, not counting net proceeds of $100.7 million from the issuance of ordinary stock in the first quarter of 2015.
- At December 31, 2014, about 220.3 million shares of ordinary stock were outstanding, not counting 21.0 million shares of ordinary stock issued in the financing in the first quarter of 2015.
Arena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena’s focus is discovering, developing and commercializing drugs to address unmet medical needs, and BELVIQ® (lorcaserin HCl) is Arena’s first internally discovered drug approved for marketing. Arena’s US operations are located in San Diego, California, and its operations outside of the United States, counting its commercial manufacturing facility, are located in Zofingen, Switzerland.
